A quasi-experimental study to estimate effectiveness of seasonal malaria chemoprevention in Aweil South County in Northern Bahr El Ghazal, South Sudan.
Amodiaquine
Effectiveness
Malaria
Seasonal malaria chemoprevention
South Sudan
Sulfadoxine–pyrimethamine
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
24 Jan 2024
24 Jan 2024
Historique:
received:
12
06
2023
accepted:
16
01
2024
medline:
25
1
2024
pubmed:
25
1
2024
entrez:
24
1
2024
Statut:
epublish
Résumé
Seasonal malaria chemoprevention (SMC) is an effective intervention to prevent malaria in children in locations where the burden of malaria is high and transmission is seasonal. There is growing evidence suggesting that SMC with sulfadoxine-pyrimethamine and amodiaquine can retain its high level of effectiveness in East and Southern Africa despite resistance concerns. This study aims to generate evidence on the effectiveness of SMC when delivered under programmatic conditions in an area with an unknown anti-malarial drug resistance profile in the Northern Bahr el-Ghazal region of South Sudan. A non-randomized quasi experimental study was conducted to compare an intervention county with a control county. Five monthly SMC cycles were delivered between July and November 2022, targeting about 19,000 children 3-59 months old. Data were obtained from repeated cross-sectional household surveys of caregivers of children aged 3-59 months using cluster sampling. Wave 1 survey took place in both counties before SMC implementation; Waves 2 and 3 took place after the second and fourth monthly SMC cycles. Difference-in-differences analyses were performed by fitting logistic regression models with interactions between county and wave. A total of 2760 children were sampled in the study across the three survey waves in both study counties. Children in the intervention arm had 70% lower odds of caregiver-reported fever relative to those in the control arm during the one-month period prior to Wave 2 (OR: 0.30, 95% CI 0.12-0.70, p = 0.003), and 37% lower odds in Wave 3 (OR: 0.63, 95% CI 0.22-1.59, p = 0.306) after controlling for baseline difference between counties in Wave 1. Odds of caregiver-reported RDT-confirmed malaria were 82% lower in the previous 1-month period prior to Wave 2 (OR: 0.18, 95% CI 0.07-0.49, p = 0.001) and Wave 3 (OR: 0.18, 95% CI 0.06-0.54, p = 0.003). These results show high effectiveness of SMC using SPAQ in terms of reducing malaria disease during the high transmission season in children 3-59 month. Despite the promising results, additional evidence and insights from chemoprevention efficacy cohort studies, and analyses of relevant resistance markers, are required to assess the suitability of SMC for this specific context.
Sections du résumé
BACKGROUND
BACKGROUND
Seasonal malaria chemoprevention (SMC) is an effective intervention to prevent malaria in children in locations where the burden of malaria is high and transmission is seasonal. There is growing evidence suggesting that SMC with sulfadoxine-pyrimethamine and amodiaquine can retain its high level of effectiveness in East and Southern Africa despite resistance concerns. This study aims to generate evidence on the effectiveness of SMC when delivered under programmatic conditions in an area with an unknown anti-malarial drug resistance profile in the Northern Bahr el-Ghazal region of South Sudan.
METHODS
METHODS
A non-randomized quasi experimental study was conducted to compare an intervention county with a control county. Five monthly SMC cycles were delivered between July and November 2022, targeting about 19,000 children 3-59 months old. Data were obtained from repeated cross-sectional household surveys of caregivers of children aged 3-59 months using cluster sampling. Wave 1 survey took place in both counties before SMC implementation; Waves 2 and 3 took place after the second and fourth monthly SMC cycles. Difference-in-differences analyses were performed by fitting logistic regression models with interactions between county and wave.
RESULTS
RESULTS
A total of 2760 children were sampled in the study across the three survey waves in both study counties. Children in the intervention arm had 70% lower odds of caregiver-reported fever relative to those in the control arm during the one-month period prior to Wave 2 (OR: 0.30, 95% CI 0.12-0.70, p = 0.003), and 37% lower odds in Wave 3 (OR: 0.63, 95% CI 0.22-1.59, p = 0.306) after controlling for baseline difference between counties in Wave 1. Odds of caregiver-reported RDT-confirmed malaria were 82% lower in the previous 1-month period prior to Wave 2 (OR: 0.18, 95% CI 0.07-0.49, p = 0.001) and Wave 3 (OR: 0.18, 95% CI 0.06-0.54, p = 0.003).
CONCLUSION
CONCLUSIONS
These results show high effectiveness of SMC using SPAQ in terms of reducing malaria disease during the high transmission season in children 3-59 month. Despite the promising results, additional evidence and insights from chemoprevention efficacy cohort studies, and analyses of relevant resistance markers, are required to assess the suitability of SMC for this specific context.
Identifiants
pubmed: 38267985
doi: 10.1186/s12936-024-04853-x
pii: 10.1186/s12936-024-04853-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
33Informations de copyright
© 2024. The Author(s).
Références
WHO. Policy recommendation: seasonal malaria chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. Geneva, World Health Organization, 2012. https://apps.who.int/iris/handle/10665/337978 . Accessed 8 Nov 2022.
WHO. Seasonal malaria chemoprevention with sulfadoxine–pyrimethamine plus amodiaquine in children: a field guide. Geneva: World Health Organization; 2013.
Baba E, Hamade P, Kivumbi H, Marasciulo M, Maxwell K, Moroso D, et al. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. Lancet. 2020;396:1829–40.
doi: 10.1016/S0140-6736(20)32227-3
Bicaba A, Serme L, Chetaille G, Kombate G, Bila A, Haddad S. Longitudinal analysis of the capacities of community health workers mobilized for seasonal malaria chemoprevention in Burkina Faso. Malar J. 2020;19:118.
doi: 10.1186/s12936-020-03191-y
pubmed: 32192499
pmcid: 7082958
Druetz T, Corneau-Tremblay N, Millogo T, Kouanda S, Ly A, Bicaba A, et al. Impact evaluation of seasonal malaria chemoprevention under routine program implementation: a quasi-experimental study in Burkina Faso. Am J Trop Med Hyg. 2018;98:524–33.
doi: 10.4269/ajtmh.17-0599
pubmed: 29260654
Druetz T. Evaluation of direct and indirect effects of seasonal malaria chemoprevention in Mali. Sci Rep. 2018;8:8104.
doi: 10.1038/s41598-018-26474-6
pubmed: 29802375
pmcid: 5970148
Ntab B, Cissé B, Boulanger D, Targett G, Lines J, Alexander N, et al. Impact of intermittent preventive anti-malarial treatment on the growth and nutritional status of preschool children in rural Senegal (West Africa). Am J Trop Med Hyg. 2007;77:411–7.
doi: 10.4269/ajtmh.2007.77.411
pubmed: 17827352
Cairns M, Ceesay SJ, Sagara I, Zongo I, Kessely H, Gamougam K, et al. Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: case–control studies in 5 countries. PLoS Med. 2021;18: e1003727.
doi: 10.1371/journal.pmed.1003727
pubmed: 34495978
pmcid: 8457484
Gilmartin C, Nonvignon J, Cairns M, Milligan P, Bocoum F, Winskill P, et al. Seasonal malaria chemoprevention in the Sahel subregion of Africa: a cost-effectiveness and cost-savings analysis. Lancet Glob Health. 2021;9:e199-208.
doi: 10.1016/S2214-109X(20)30475-7
pubmed: 33482140
Nuwa A, Baker K, Bonnington C, Odongo M, Kyagulanyi T, Bwanika JB, et al. A non-randomized controlled trial to assess the protective effect of SMC in the context of high parasite resistance in Uganda. Malar J. 2023;22:63.
doi: 10.1186/s12936-023-04488-4
pubmed: 36814301
pmcid: 9945593
WHO. World malaria report 2022. Geneva, World Health Organization, 2022. https://www.who.int/teams/global-malaria-programme
WHO. South Sudan’s first national malaria conference unites Government and partners to renew efforts towards ending malaria. Geneva: World Health Organization; 2022.
Androga DA. A literature review about the impact of climate change on malaria in south Sudan. South Sudan Med J. 2020;13:193–5.
MOH. Republic of South Sudan Malaria Indicator Survey (MIS) 2017. 2017. https://www.malariasurveys.org/documents/SSMIS2017finalreport20190520_signed.pdf
UNICEF. The climate crisis is a child’s rights crisis. United Nations Children’s Fund, Race to Zero. 2021. https://www.unicef.org/media/105376/file/UNICEF-climate-crisis-child-rights-crisis.pdf
Pasquale HA. Malaria prevention strategies in South Sudan. South Sudan Med J. 2020;13:187–90.
Doctors without borders. Aweil Seasonal Malaria Chemoprevention Report. 2022.
Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50:217–26.
doi: 10.1097/MLR.0b013e3182408812
pubmed: 22310560
pmcid: 3731143
Zhou H, Taber C, Arcona S, Li Y. Difference-in-differences method in comparative effectiveness research: utility with unbalanced groups. Appl Health Econ Health Policy. 2016;14:419–29.
doi: 10.1007/s40258-016-0249-y
pubmed: 27371369
pmcid: 4937082
Dobility Inc. SurveyCTO: a reliable, secure, and scalable mobile data collection platform for researchers and professionals. https://www.dobility.com/
Nnaji C. Coverage and quality of seasonal malaria chemoprevention supported by Malaria Consortium in 2022. https://www.malariaconsortium.org/media-download-file/202304251219/2022malariaconsortiumsmccoveragereport.pdf
Mokken RJ. A theory and procedure of scale analysis. Berlin, New York: De Gruyter Mouton; 1971.
doi: 10.1515/9783110813203
StataCorp. Stata statistical software: Release 17. TX:StataCorp; 2021.
Kweku M, Liu D, Adjuik M, Binka F, Seidu M, Greenwood B, et al. Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial. PLoS ONE. 2008;3: e4000.
doi: 10.1371/journal.pone.0004000
pubmed: 19098989
pmcid: 2602973
van Lenthe M, van der Meulen R, Lassovski M, Ouabo A, Bakula E, Badio C, et al. Markers of sulfadoxine-pyrimethamine resistance in Eastern Democratic Republic of Congo; implications for malaria chemoprevention. Malar J. 2019;18:430.
doi: 10.1186/s12936-019-3057-7
pubmed: 31852480
pmcid: 6921399
WHO. Guidelines for malaria, 3 June 2022. Geneva, World Health Organization, 2022. https://apps.who.int/iris/handle/10665/354781 . Accessed 8 Nov 2022.
UNICEF. Climate change and flooding: responding to the needs of growing number of children and families affected by floods. 2021. https://www.unicef.org/southsudan/what-we-do/climate-change-and-flooding https://www.unicef.org/southsudan/what-we-do/climate-change-and-flooding .
Ambe JP, Balogun ST, Waziri MB, Nglass IN, Saddiq A. Impacts of seasonal malaria chemoprevention on malaria burden among under five-year-old children in Borno State, Nigeria. J Trop Med. 2020;2020:9372457.
doi: 10.1155/2020/9372457
pubmed: 32665781
pmcid: 7349624
McCoy CE. Understanding the intention-to-treat principle in randomized controlled trials. Western J Emerg Med. 2017;18:1075–8.
doi: 10.5811/westjem.2017.8.35985